Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | PRKCG | P05129 | 2/20 | 0.40 |
| ▸ | PRKCB | P05771 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | PRKCH | P24723 | 2/20 | 0.40 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306291 | 0.81 | PRKCZ (0.35) | LMNAALDH1A1HTTTRPV1CYP3A4 | |
| SCHEMBL1453289 | 0.80 | HTR1B (0.40) | ALDH1A1HTTKDM4EGLASMN1; SMN2 | |
| SCHEMBL15941363 | 0.75 | KDM4E (0.53) | LMNAALDH1A1HTTCYP3A4CYP2D6 | |
| SCHEMBL29720231 | 0.75 | KDM4E (0.53) | LMNAALDH1A1HTTCYP3A4CYP2D6 | |
| SCHEMBL6114998 | 0.73 | TRPV1 (0.51) | LMNAALDH1A1HTTTRPV1CYP3A4 | |
| SCHEMBL29094112 | 0.73 | MEN1 (0.37) | LMNAALDH1A1KDM4ECYP1A2MAPT | |
| SCHEMBL6729852 | 0.72 | L3MBTL1 (0.36) | CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6114809 | 0.72 | TRPV1 (0.52) | LMNAALDH1A1HTTTRPV1CYP3A4 | |
| SCHEMBL29230986 | 0.72 | KCNH2 (0.33) | — | |
| SCHEMBL994930 | 0.71 | LOXL2 (0.42) | CYP3A4CYP2D6CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2421882-A2 | ANGIOGENESIS INHIBITORS | President and Fellows of Harvard College (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123545-A2 | ANGIOGENESIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | LMNA 4612/4885ALDH1A1 614/4885HTT 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.